Sydney, Australia, 26 February 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company is pleased to announce that the Phase 1 clinical trial data for its B cell peptide cancer vaccine B-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The title of the article is "Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors," and is primarily authored by Imugene’s SAB members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.

This first-in-human Phase 1 study evaluated the safety profile, optimal immunologic/biologic dose (OID/OBD) and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzumab and pertuzumab HER-2 binding sites. While the billion dollar blockbusters marketed by Roche/Genentech Herceptin® and Perjeta® have been approved for clinical use, patients often develop resistance to these therapies. Professor Pravin Kaumaya commented, “We have advanced a new paradigm in immunotherapy that focuses on humoral responses based on conformational B-cell epitope vaccines”.

“The study vaccine is safe, exhibits anti-tumor activity and shows preliminary indications that peptide vaccination may avoid therapeutic resistance and offers a promising alternative to monoclonal antibody therapies”, Professor Kaumaya added.

For further information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
Appendix

Full online details of the manuscript can be found at http://clincancerres.aacrjournals.org/. OnlineFirst articles are published online before they appear in a regular issue of the journal.

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Patients with Advanced Solid Tumors

Tanios Bekaii-Saab ¹, Robert Wesolowski ², Daniel H. Ahn ¹, Christina Wu ³, Amir Mortazavi ², Maryam Lustberg ², Bhuvaneswari Ramaswamy ², Jeffrey Fowler ⁴, Lai Wei ⁵, Jay Overholser ⁴ and Pravin T.P. Kaumaya ⁴

Author Affiliations:
1 Mayo Clinic, Department of Internal Medicine 5777 E Mayo Boulevard Phoenix, AZ 85054
2 The Ohio State University, Department of Internal Medicine, Division of Medical Oncology 320 W 10th Avenue, Columbus, OH 43210
3 Emory University School of Medicine, Department of Hematology & Medical Oncology 201 Dowman Drive, Atlanta GA 30322
4 The Ohio State University, Department of Obstetrics & Gynecology 316 TMRF, 420 W 12th Avenue, Columbus, OH 43210
5 The Ohio State University, Center for Biostatistics 1800 Cannon Drive, Columbus, OH 43210

Running Title: Phase 1 immunotherapy trial with two B-cell vaccines

Financial support:
NIH/NCI R01 CA CA84356 to PTPK; NIH R21 CA13508 to PTPK

Corresponding Author:
Pravin T.P. Kaumaya, Ph.D.
Professor and Director in the Division of Vaccine Research
OSU Department of Obstetrics and Gynecology
316 TMRF, 420 W. 12th Ave., Columbus, OH 43210
Tel: 614-292-7028
Fax: 614-292-1135
Email: pravin.kaumaya@osumc.edu
About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.